Moderna, Inc. (MRNA) Thursday reported significantly lower profit for the fourth quarter than last year, primarily driven by decrease in revenue on lower Covid-19 product sales. However, the company's profit as well revenue beat the Street view.
Net income was $217 million or $0.55 per share for the fourth quarter, compared with $1.465 billion or $3.61 per share in the same quarter a year ago. On average, 17 analysts polled by Thomson-Reuters were expecting for a loss of $0.97 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenue for the fourth quarter was $2.811 billion, a sharp decrease from $5.084 billion in the same period last year, primarily due to a reduction in sales of the company's COVID-19 vaccine. The consensus estimate was for $2.49 billion.
Net product sales were $2.8 billion, 43% down from the previous year.
Looking ahead, Moderna has reiterated its full-year product sales outlook of about $4 billion.
Moderna shares were up more than 6 percent in pre-market. The stock had closed at $87.59, up 0.69 percent on Wednesday. It has traded in the range of $62.55 - $163.24 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.